Product
CK-3773274
Aliases
CK-3773274 (10 - 30 mg), CK-3773274 (5 - 15 mg), CK-3773274 (5 - 20 mg), CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)
3 clinical trials
2 indications
Indication
Hypertrophic CardiomyopathyIndication
Obstructive Hypertrophic CardiomyopathyClinical trial
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic CardiomyopathyStatus: Completed, Estimated PCD: 2023-02-28
Clinical trial
A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract ObstructionStatus: Completed, Estimated PCD: 2023-12-01
Clinical trial
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment of Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)Status: , Estimated PCD: 2026-03-01